Classical and innovative drugs for the treatment of Leishmania infections DOI Creative Commons

Wanessa J. S. Mota,

Beatriz N. Guedes,

Sona Jain

и другие.

Deleted Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Окт. 7, 2024

Abstract Although among the six most common parasitic diseases, leishmaniasis is considered a neglected disease, being recognised as serious public health burden worldwide. This fact impairs technological advancements and investments in innovative therapeutic approaches, so that commonly available drugs are still associated with low rates significant side effects. Pentavalent antimonials, such Pentostan ® Glucantime , were established chemotherapeutic agents since 1940s, first line of treatment for leishmaniasis; however, 60% cases resistant to pentavalent antimonials. Thus, search more effective therapies new potential leishmanicidal activity in-demand. In this review, an overview about disease its pathophysiology given, discussing current state-of-the-art standard treatments alternatives based on drug delivery enhancing need pharmaceutical treatments.

Язык: Английский

Bisphosphonate-Based Molecules as Potential New Antiparasitic Drugs DOI Creative Commons
Joice Castelo Branco Santos,

Jonathas Alves de Melo,

Sweta Maheshwari

и другие.

Molecules, Год журнала: 2020, Номер 25(11), С. 2602 - 2602

Опубликована: Июнь 3, 2020

Neglected tropical diseases such as Chagas disease and leishmaniasis affect millions of people around the world. Both various parts globe drugs traditionally used in therapy against these have limitations, especially with regard to low efficacy high toxicity. In this context, class bisphosphonate-based compounds has made significant advances regarding chemical synthesis process well pharmacological properties attributed compounds. Among spectrum activity, bisphosphonate antiparasitic activity stand out, treatment caused by Trypanosoma cruzi Leishmania spp., respectively. Some can inhibit mevalonate pathway, an essential metabolic interfering ergosterol, a sterol responsible for growth viability parasites. Therefore, review aims present information about importance agents potential new treat leishmaniasis.

Язык: Английский

Процитировано

24

Extracellular Vesicles during TriTryps infection: Complexity and future challenges DOI
Izadora Volpato Rossi,

Maria Alice Ferreira Nunes,

Sandra Vargas-Otalora

и другие.

Molecular Immunology, Год журнала: 2021, Номер 132, С. 172 - 183

Опубликована: Фев. 15, 2021

Язык: Английский

Процитировано

21

Drug Repurposing in Chagas Disease: Chloroquine Potentiates Benznidazole Activity against Trypanosoma cruzi In Vitro and In Vivo DOI
Ramendra Pati Pandey, Marilda Savóia Nascimento, Caio Haddad Franco

и другие.

Antimicrobial Agents and Chemotherapy, Год журнала: 2022, Номер 66(11)

Опубликована: Окт. 31, 2022

Drug combinations and drug repurposing have emerged as promising strategies to develop novel treatments for infectious diseases, including Chagas disease. In this study, we aimed investigate whether the repurposed drugs chloroquine (CQ) colchicine (COL), known inhibit Trypanosoma cruzi infection in host cells, could boost anti- T. effect of trypanocidal benznidazole (BZN), increasing its therapeutic efficacy while reducing dose needed eradicate parasite. The combination BZN COL exhibited cytotoxicity infected cells low antiparasitic activity.

Язык: Английский

Процитировано

15

Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps DOI Creative Commons
Thalia Pacheco‐Fernández,

Hannah L. Markle,

Chaitenya Verma

и другие.

Research and Reports in Tropical Medicine, Год журнала: 2023, Номер Volume 14, С. 61 - 85

Опубликована: Июль 1, 2023

Leishmaniasis is a neglected tropical disease endemic primarily to low-and middle-income countries, for which there has been inadequate development of affordable, safe, and efficacious therapies.Clinical manifestations leishmaniasis range from selfhealing skin lesions lethal visceral infection with chances relapse.Although treatments are available, secondary effects limit their use outside the clinic negatively impact quality life patients in areas.Other non-medicinal treatments, such as thermotherapies, limited cutaneous but not infection.Recent studies shed light mechanisms through Leishmania can persist by hiding cellular safe havens, even after chemotherapies.This review focuses on exploring niches that parasites may be leveraging within host.Also, cellular, metabolic, molecular implications how those could targeted therapeutic purposes discussed.Other therapies, developed against cancer or manipulation ferroptosis pathway, proposed possible due action.In particular, target hematopoietic stem cells monocytes, have recently found necessary components sustain provide niche discussed this potential field-deployable leishmaniasis.

Язык: Английский

Процитировано

9

Classical and innovative drugs for the treatment of Leishmania infections DOI Creative Commons

Wanessa J. S. Mota,

Beatriz N. Guedes,

Sona Jain

и другие.

Deleted Journal, Год журнала: 2024, Номер 21(1)

Опубликована: Окт. 7, 2024

Abstract Although among the six most common parasitic diseases, leishmaniasis is considered a neglected disease, being recognised as serious public health burden worldwide. This fact impairs technological advancements and investments in innovative therapeutic approaches, so that commonly available drugs are still associated with low rates significant side effects. Pentavalent antimonials, such Pentostan ® Glucantime , were established chemotherapeutic agents since 1940s, first line of treatment for leishmaniasis; however, 60% cases resistant to pentavalent antimonials. Thus, search more effective therapies new potential leishmanicidal activity in-demand. In this review, an overview about disease its pathophysiology given, discussing current state-of-the-art standard treatments alternatives based on drug delivery enhancing need pharmaceutical treatments.

Язык: Английский

Процитировано

3